BioNTech完成对Biotheus的收购-动脉网

BioNTech Completes Acquisition of Biotheus

BioNTech 等信源发布 2025-02-03 20:18



可切换为仅中文







Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform

收购以加强BioNTech肿瘤学战略的关键支柱，旨在建立BNT327作为泛肿瘤技术平台

for the treatment of advanced cancers

With the closing of the transaction, BioNTech will expand its capabilities to develop, manufacture and commercialize novel BNT327 combinations and next-generation bispecific antibodies

随着交易的完成，BioNTech将扩大其开发、制造和商业化新型BNT327组合和下一代双特异性抗体的能力

Biotheus will become a new indirect Chinese subsidiary of BioNTech, adding a local research and development hub and an advanced biologics manufacturing facility to the Company’s network

Biotheus将成为BioNTech在中国的一家新的间接子公司，在公司网络中增加一个当地的研发中心和一个先进的生物制品制造设施

MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE)

德国梅因茨，2025年2月3日 (GLOBE NEWSWIRE)

BioNTech SE

BioNTech SE 公司

(Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus (“Biotheus”), a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.

（纳斯达克：BNTX，“BioNTech”或“该公司”）今天宣布完成对Biotheus（“Biotheus”）的收购，Biotheus是一家临床阶段的生物技术公司，致力于发现和开发新型抗体，以解决肿瘤或炎症患者未满足的医疗需求。疾病。

The acquisition was announced on .

此次收购于日宣布。

November 2024

2024年11月

and builds on the successful collaboration on the late-stage clinical asset BNT327, an investigational bispecific antibody targeting PD-L1 and VEGF-A, and other bispecific antibody candidates.

并建立在晚期临床资产BNT327的成功合作基础上，BNT327是一种靶向PD-L1和VEGF-A的研究性双特异性抗体，以及其他双特异性抗体候选物。

The transaction is part of BioNTech’s oncology strategy, aimed at expanding the Company’s capabilities to research, develop and commercialize BNT327 as a pan-tumor technology platform for combination therapies. With this completion of the acquisition, BioNTech obtains full global rights to BNT327 and rights to all other candidates of Biotheus’ pipeline as well as to its in-house antibody generation platform and bispecific antibody drug conjugate capability.

该交易是BioNTech肿瘤学战略的一部分，旨在扩大公司的能力，将BNT327作为联合治疗的泛肿瘤技术平台进行研究，开发和商业化。收购完成后，BioNTech获得了BNT327的全部全球权利，以及Biotheus管道的所有其他候选人的权利，以及其内部抗体生成平台和双特异性抗体-药物缀合物能力。

Biotheus will operate as a new indirect Chinese subsidiary of BioNTech, adding a local research and development hub and an advanced biologics manufacturing facility to the Company’s network. .

Biotheus将作为BioNTech在中国的一家新的间接子公司运营，在公司网络中增加一个本地研发中心和一个先进的生物制品制造设施。

The total consideration to acquire 100 percent of the issued share capital by Biotheus amounts to $800 million, predominantly in cash, with a small portion in BioNTech American Depositary Shares, plus additional performance-based payments of up to $150 million if certain milestones are met.

Biotheus收购100%已发行股本的总对价为8亿美元，主要是现金，其中一小部分是BioNTech美国存托股，如果达到某些里程碑，还将支付高达1.5亿美元的额外业绩付款。

About BNT327

关于BNT327

BNT327 is a novel investigational bispecific antibody combining two complementary, validated mechanisms in oncology into one single molecule. BNT327 combines PD-L1 checkpoint inhibition aimed at restoring T cells’ ability to recognize and destroy tumor cells with the neutralization of VEGF-A. The blocking of VEGF-A is aimed at reversing the tumor’s immuno-suppressive effect in its microenvironment and cutting off the blood and oxygen supply that feeds tumor cells (anti-angiogenesis effect), with the intention of preventing the tumor from growing and proliferating.

BNT327是一种新型研究性双特异性抗体，将肿瘤学中两种互补的，经过验证的机制结合到一个分子中。。

BNT327 may be differentiated via its mechanism of action of targeting PD-L1 on the tumor cells aimed at enriching BNT327 in the tumor microenvironment and promoting localized anti-cancer activity. The co-localized blockade of the PD-(L)1 pathway and the VEGF-A driven formation of an immuno-suppressive microenvironment has been shown to deliver synergistically enhanced anti-tumor immune responses in several solid tumor types..

BNT327可以通过其靶向PD-L1对肿瘤细胞的作用机制来分化，旨在富集肿瘤微环境中的BNT327并促进局部抗癌活性。。。

More than 750 patients have been treated with BNT327 in clinical trials to date. Multiple clinical trials are currently ongoing evaluating BNT327 either as a monotherapy or in combination with other treatment modalities targeting different oncogenic pathways in various solid tumor indications. Multiple global trials are ongoing or planned to start in 2025, including three global clinical trials with registrational potential in first-line small cell lung cancer (“SCLC”), non-small cell lung cancer (“NSCLC”) and triple-negative breast cancer (“TNBC”).

迄今为止，已有750多名患者在临床试验中接受了BNT327治疗。目前正在进行多项临床试验，评估BNT327作为单一疗法或与针对各种实体瘤适应症中不同致癌途径的其他治疗方式相结合。多项全球试验正在进行中或计划于2025年开始，包括三项具有一线小细胞肺癌（“SCLC”）、非小细胞肺癌（“NSCLC”）和三阴性乳腺癌（“TNBC”）注册潜力的全球临床试验。

Additional trials will explore combining BNT327 and BioNTech’s proprietary antibody-drug conjugate candidates (“ADCs”). If successfully developed and approved, BioNTech aims to use this bispecific antibody candidate as a next-generation immuno-oncology (“IO”) backbone in combination with other treatment modalities targeting a broad range of cancer indications..

其他试验将探索结合BNT327和BioNTech专有的抗体-药物偶联物候选物（“ADC”）。如果成功开发并获得批准，BioNTech旨在将这种双特异性抗体候选物用作下一代免疫肿瘤学（“IO”）骨架，并与针对多种癌症适应症的其他治疗方式相结合。。

About BioNTech

关于BioNTech

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms with the intent of rapid development of novel biopharmaceuticals.

生物制药新技术（BioNTech）是一家全球下一代免疫治疗公司，开创了针对癌症和其他严重疾病的新型研究疗法。BioNTech利用各种计算发现和治疗药物平台，旨在快速开发新型生物制药。

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules.

其广泛的肿瘤学产品候选组合包括个体化和现成的基于mRNA的疗法，创新的嵌合抗原受体（CAR）T细胞，几种基于蛋白质的疗法，包括双特异性免疫检查点调节剂，靶向癌症抗体和抗体-药物缀合物（ADC）疗法，以及小分子。

Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron..

基于其在mRNA疫苗开发和内部制造能力方面的深厚专业知识，BioNTech及其合作者正在研究和开发多种候选mRNA疫苗，用于多种传染病以及多种肿瘤学管道。BioNTech与多家全球专业制药合作伙伴建立了广泛的关系，包括DualityBio、复星制药、Genentech、罗氏集团成员、Genevant、Genmab、MediLink、OncoC4、辉瑞和Regeneron。。

For more information, please visit

有关更多信息，请访问

www.BioNTech.com

BioNTech Forward-Looking Statements

BioNTech前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning expectations regarding the impact of this acquisition on BioNTech’s business; the creation of long-term value for BioNTech and Biotheus shareholders; potential synergies between BioNTech and Biotheus and their businesses; BioNTech’s ability to research, develop and potentially commercialize BNT327 and potentially other assets in Biotheus’ pipeline; the expansion of BioNTech’s operations in China; the initiation, timing, progress, results, and cost of BioNTech’s research and development programs, including BioNTech’s current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech’s expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; discussions with regulatory agencies; BioNTech’s expectations with respect to intellectual property; and the impact of BioNTech’s collaboration and licensing agreements.

本新闻稿包含1995年《私人证券诉讼改革法案》修订版所指的前瞻性声明，包括但不限于关于此次收购对BioNTech业务影响的预期声明；为BioNTech和Biotheus股东创造长期价值；BioNTech和Biotheus及其业务之间的潜在协同作用；BioNTech研究、开发和潜在商业化BNT327以及Biotheus管道中潜在的其他资产的能力；BioNTech在中国的业务扩张；BioNTech研发计划的启动、时间安排、进度、结果和成本，包括BioNTech当前和未来的临床前研究和临床试验，包括关于研究或试验的预期启动、注册和完成时间以及相关准备工作和结果的可用性的声明，以及监管批准和营销授权申请的时间和结果；BioNTech对肿瘤学未来潜在商业化的期望，包括关于时间和适应症的目标；额外潜在注册试验的目标时间和数量，以及任何试验BioNTech可能启动的注册潜力；与监管机构的讨论；BioNTech对知识产权的期望；以及BioNTech合作和许可协议的影响。

In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although .

在某些情况下，前瞻性陈述可以通过术语来识别，例如“意志”、“可能”、“应该”、“期望”、“打算”、“计划”、“目标”、“预期”、“相信”、“估计”、“预测”、“潜在”、“继续”或这些术语的否定或其他类似术语。

You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended September 30, 2024 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at

您应该查看BioNTech在表6-K中截至2024年9月30日的报告以及BioNTech随后向SEC提交的文件中“风险因素”标题下描述的风险和不确定性，这些文件可在SEC网站上找到

www.sec.gov

. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise..

这些前瞻性声明仅在本协议签署之日有效。除法律要求外，BioNTech不承担在新信息、未来发展或其他情况下更新或修改本新闻稿中包含的任何前瞻性声明的任何意图或责任。。

CONTACTS

联系人

Investor Relations

投资者关系

Michael Horowicz

迈克尔霍罗维奇

Investors@biontech.de

Media Relations

媒体关系

Jasmina Alatovic

Jasmina Alatovic 的